Literature DB >> 17024599

Hyperhomocysteinemia and venous thromboembolism.

Marco Cattaneo1.   

Abstract

Homocysteine (Hcy) is a sulfhydryl amino acid derived from the metabolic conversion of methionine, which is dependent on vitamins (folic acid, B12 and B6) as cofactors or cosubstrates. Severe hyperhomocysteinemia (homocystinuria), due to inherited metabolic defects of Hcy metabolism, is associated with very high risk of venous thromboembolism (VTE); treatment with vitamins is associated with dramatic decrease of VTE risk. Several case-control and prospective studies showed that also mild/moderate hyperhomocysteinemia (which is caused by the interaction of environmental factors with mild genetic abnormalities of Hcy metabolism) is associated with heightened risk of VTE; however, it is uncertain whether treatment with vitamins also decreases the VTE risk in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17024599     DOI: 10.1055/s-2006-951456

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  17 in total

Review 1.  Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management.

Authors:  Anna K Jönsson; Olav Spigset; Staffan Hägg
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

Review 2.  Epidemiology and risk factors for venous thrombosis.

Authors:  Mary Cushman
Journal:  Semin Hematol       Date:  2007-04       Impact factor: 3.851

3.  A prospective study on hyperhomocysteinemia as an aggravating factor in chronic venous insufficiency.

Authors:  Maria Rotaru; Gabriela Mariana Iancu; Ioana Baldovin
Journal:  Exp Ther Med       Date:  2022-05-17       Impact factor: 2.751

4.  Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte.

Authors:  James D Weisfeld-Adams; Mark A Morrissey; Brian M Kirmse; Bobbie R Salveson; Melissa P Wasserstein; Peter J McGuire; Sherlykutty Sunny; Jessica L Cohen-Pfeffer; Chunli Yu; Michele Caggana; George A Diaz
Journal:  Mol Genet Metab       Date:  2009-09-27       Impact factor: 4.797

Review 5.  MTHFR: Addressing Genetic Counseling Dilemmas Using Evidence-Based Literature.

Authors:  Brooke Levenseller Levin; Elizabeth Varga
Journal:  J Genet Couns       Date:  2016-04-30       Impact factor: 2.537

Review 6.  [Diagnostic assessment of perioperative thromboembolism].

Authors:  Thomas Lang
Journal:  Wien Med Wochenschr       Date:  2009-10

7.  Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.

Authors:  F S Falvella; C Cremolini; R Miceli; F Nichetti; S Cheli; C Antoniotti; G Infante; A Martinetti; F Marmorino; E Sottotetti; R Berenato; M Caporale; A Colombo; F de Braud; M Di Bartolomeo; E Clementi; F Loupakis; F Pietrantonio
Journal:  Pharmacogenomics J       Date:  2016-03-22       Impact factor: 3.550

8.  Antipsychotics and risk of venous thromboembolism: A population-based case-control study.

Authors:  Anna K Jönsson; Erzsebet Horváth-Puhó; Staffan Hägg; Lars Pedersen; Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2009-08-09       Impact factor: 4.790

9.  Impact of Inherited Prothrombotic Disorders on the Long-Term Clinical Outcome of Percutaneous Transluminal Angioplasty in Patients with Diabetes.

Authors:  Michal Dubský; Alexandra Jirkovská; Libuše Pagáčová; Robert Bém; Andrea Němcová; Vladimíra Fejfarová; Veronika Wosková; Edward B Jude
Journal:  J Diabetes Res       Date:  2015-07-13       Impact factor: 4.011

10.  What Could be the Most Advantageous Therapeutic Approach to Avoid both Arterial and Venous Thrombosis in Hyperhomocysteinemia?

Authors:  Federico Cacciapuoti
Journal:  Curr Cardiol Rev       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.